Jennison Associates LLC Cuts Position in AbbVie Inc. $ABBV

Jennison Associates LLC decreased its position in AbbVie Inc. (NYSE:ABBV) by 36.1% during the second quarter, HoldingsChannel.com reports. The fund owned 679,544 shares of the company’s stock after selling 383,188 shares during the quarter. Jennison Associates LLC’s holdings in AbbVie were worth $171,000,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ABBV. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID grew its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie in the 4th quarter worth about $31,000. Finally, Abound Financial LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at about $32,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of analyst reports. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Barclays upped their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. UBS Group boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, Piper Sandler increased their price target on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

AbbVie Trading Down 1.5%

Shares of NYSE:ABBV opened at $261.88 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The company has a market capitalization of $462.69 billion, a price-to-earnings ratio of 73.98, a PEG ratio of 0.88 and a beta of 0.30. The firm’s 50-day moving average is $247.72 and its 200 day moving average is $227.22.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reached a new 52-week high. The move above its previous July peak signals continued buying interest and reinforces the stock’s strong uptrend. ABBV is trading well above its 50-day and 200-day moving averages. AbbVie Hits a New 52-Week High
• Positive Sentiment: Analysts and dividend investors remain constructive on ABBV. AbbVie has gained about 19% in 2026, while its $1.73 quarterly dividend provides an annualized payout of $6.92 per share. Recent analyst views include buy ratings and price targets as high as $300, supporting the bullish case. Dividend Giants Pfizer, Chevron, AbbVie
• Positive Sentiment: AbbVie completed a $10 billion senior-notes offering to help fund its Apogee Therapeutics acquisition. The financing supports expansion of AbbVie’s immunology and specialty-medicine pipeline, potentially helping offset future pressure from Humira competition. AbbVie Completes Senior Notes Offering
• Neutral Sentiment: AbbVie paid €370 million in Irish corporation tax last year. The disclosure highlights the company’s significant Irish operations but is unlikely to materially change near-term earnings expectations. AbbVie Irish Corporation Tax
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million. The transaction reduced his direct holdings by about 30.5%. Although it may reflect personal financial planning, the sizable sale can weigh modestly on sentiment, particularly after the stock’s strong rally. AbbVie Insider Selling
• Negative Sentiment: The Apogee acquisition financing increases AbbVie’s leverage. Investors will evaluate higher interest costs and whether Apogee’s pipeline can generate sufficient returns. ABBV also trades at a high earnings multiple, leaving less room for disappointing results.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.